US non-profit the Peterson Centre on Healthcare has launched a new institute, backed with $50 million in funding, that will take a close look at the clinical benefits and
Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales.
The EU’s joint clinical assessment (JCA) initiative has been set up to accelerate patient access to new therapies, but could end up restricting the use of new technologies
Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this ye
The NHS has agreed a pair of commercial deals with Merck & Co/MSD and Eisai that will allow hundreds of women with advanced endometrial cancer to get access to life-ex